DAWN Archived Articles
Day One Biopharmaceuticals (NASDAQ:DAWN): A Commercial-Stage Oncology Company with Promising Pipeline and Robust Financials
Published on March 08, 2025
Day One Biopharmaceuticals (DAWN): Unlocking the Potential of Targeted Therapies for Life-Threatening Diseases
Published on November 06, 2024
Day One Biopharmaceuticals, Inc. (DAWN): A Promising Oncology Player Navigating the Competitive Landscape
Published on September 24, 2024